Results 11 to 20 of about 39,006,954 (221)
, 1989 Eighty-five breast carcinomas from the same number of patients have been assessed immunohistochemically using the antiserum 21N for the presence of the c-erbB-2 protein.
R. A. Walker (7606157) +2 more
core +8 more sources
c-erbB-2 expression in benign and malignant breast disease. [PDF]
, 1988 An antibody, 21N, raised against a synthetic peptide from the predicted sequence of the c-erbB-2 protein has been used immunocytochemically in a retrospective study of formalin fixed paraffin embedded breast biopsies.
Gusterson, BA +17 more
core +1 more source
Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy [PDF]
, 2002 Concentrations of soluble c-erbB-2 were determined in the sera of 64 patients with distant metastasis from advanced breast cancer receiving second-line hormone or chemotherapy in comparison to 35 breast cancer patients without detectable recurrent ...
Classen, S. +5 more
core +1 more source
Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network. [PDF]
, 2013 There is increasing evidence that opioid analgesics may interfere with tumour growth. It is currently thought that these effects are mediated by transactivation of receptor tyrosine kinase (RTK)-controlled ERK1/2 and Akt signalling.
Weingaertner, Inka Regine +5 more
core +1 more source
C-erbB-2 in Serum of Patients Receiving Fractionated Paclitaxel Chemotherapy
The International Journal of Biological Markers, 1999 Humanized anti-c-erbB-2 antibodies (Herceptin®) in a weekly schedule are a new therapeutic option for the treatment of c-erbB-2-positive, advanced breast cancer (ABC).
D. Lüftner, S. Schnabel, K. Possinger
doaj +1 more source
A new model for ductal carcinoma in situ suggests strategies for treatment [PDF]
, 2002 Human ductal carcinoma in situ (DCIS) of the breast is now diagnosed quite frequently, due largely to the introduction of mammographic screening. It has been shown in a cell culture system that activation of c-erbB-2, but not the epidermal growth factor ...
Gullick, William J.
core +1 more source
C-erbB-2 Oncoprotein in Gastric Carcinoma: Correlation with Clinical Stage and Prognosis
The International Journal of Biological Markers, 2001 The aim of this study was to investigate the expression of the oncogene c-erbB-2 in gastric tumors. Immunohistochemical study of the expression of c-erbB-2 was performed in formalin-fixed, paraffin-embedded sections from 82 gastric adenocarcinomas using ...
C.T.F. Oshima +3 more
doaj +1 more source
Diagnostic Pathology, 2010 Background Endometrial carcinoma (EC) is the most common malignancy of the female genital tract. Gene alterations and overexpression of various oncogenes are important in tumor development.
Kandemir Nilufer +6 more
doaj +1 more source
The International Journal of Biological Markers, 1993 Selected murine monoclonal antibodies (MAb) have been shown to inhibit relevant tumor growth in vitro and in animal models. Recently, bispecific antibodies (BsMAb) have been developed which target cytolytic effector cells via one antibody binding site ...
I. Garcia De Palazzo +2 more
doaj +1 more source
JAI (Jurnal Anestesiologi Indonesia), 2009 Latar Belakang: Nyeri akut paska bedah memicu timbulnya gejala klinis patofisiologis, menekan respon imun, sehingga menyebabkan penurunan sistem imun yang akan menghambat penyembuhan luka. Levobupivakain, anestetik lokal durasi panjang efektif mengurangi
Curniawati Trisasi, Marwoto Marwoto
doaj +1 more source